Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.

Jocelyn Garcia-Sayre,Yvonne G Lin,Koji Matuso,Denice D Tsao-Wei,Paulette Mhawech-Fauceglia,Stan Louie,Tiange Dong,Marcia A Ciccone,Laurie L Brunette-Masi,Huyen Q Pham,Annie A Yessaian,Susan G Groshen,Grace Facio,Marissa Aldana,Laila I Muderspach,Agustin A Garcia,Lynda D Roman

Gynecologic oncology（2023）

引用 0|浏览16

暂无评分

摘要

Eribulin shows modest activity in patients with recurrent/advanced cervical cancer with a favorable toxicity profile. Prior paclitaxel exposure is associated with decreased eribulin response. βII, βIII tubulin subtypes and BAX are predictors of response and survival. Eribulin may be an option for women with paclitaxel-naïve recurrent/advanced cervical cancer.

查看译文

关键词

Biomarkers,Cervical cancer,Chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要